Intravenous Catheter Declotting: Same Outcomes With Lower Dose Urokinase?

Journal of Infusion Nursing

Volumn 26, Issue 4, 2003, Pages 245-251

  Juvé, Maria Eulàlia ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE; UROKINASE ROGER; UROKINASE VEDIM;

ADULT; ARTICLE; CENTRAL VENOUS CATHETER; ECONOMIC ASPECT; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; INTRAVENOUS CATHETER; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PERIPHERALLY INSERTED CENTRAL VENOUS CATHETER; PRIORITY JOURNAL; VASCULAR PATENCY; CATHETERIZATION; CENTRAL VENOUS CATHETERIZATION; CLINICAL NURSING RESEARCH; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DOSE RESPONSE; ECONOMICS; EQUIPMENT; INDWELLING CATHETER; LAVAGE; METHODOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOSIS; TIME; TREATMENT OUTCOME;

ADULT; CATHETERIZATION, CENTRAL VENOUS; CATHETERIZATION, PERIPHERAL; CATHETERS, INDWELLING; CLINICAL NURSING RESEARCH; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; EQUIPMENT FAILURE; FEMALE; HUMANS; IRRIGATION; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATORS; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME; URINARY PLASMINOGEN ACTIVATOR; VASCULAR PATENCY;

EID: 0043237754     PISSN: 15331458     EISSN: None     Source Type: Journal    
DOI: 10.1097/00129804-200307000-00010     Document Type: Article

References (49)

1. O'Grady NP, Alexander M, Patchen Dellinger E, et al. Draft guidelines for the prevention of intravascular catheter-related infections. CDC HICPAC August 2001. Available at: www.cdc. gov. Accessed November 20, 2001.
2. Raad II, Bodey GP. Infectious complications of indwelling vascular catheters. Clin Infect Dis. 1992;15:197-208.
3. Maki DG, Ringer M, Alvarado CJ. Prospective, randomised trial of povidone-iodine, alcohol and chlorehexidine for prevention of infection associated with central venous and arterial catheters. Lancet. 1991;338:339-343.
4. Ray CE, Jr. Infection control principles and practices in the care and management of central venous devices. J Intraven Nurs. June 1999; 22(supp):S18-S25.
5. Wickham R, Purl S, Welker D. Long-term central venous catheters: issues for care. Semin Oncol Nurs. 1992;8(2):133-147.
6. Evans Orr M. Issues in the management of percutaneous central venous catheters. Single and multiple lumens. Nurs Clin North Am. 1993;28(4):911-919.
7. Nace CS, Ingle RJ. Central venous catheter "pinch-off" and fracture: a review of two under-recognized complications. Oncol Nurs Forum. 1993;20(8):1227-1235.
8. Andris DA, Krzywda EA. Catheter pinch-off syndrome: recognition and management. J Intraven Nurs. 1997;20:233-237.
9. Seery Cunningham R, Bonam-Crawford D. The role of fibrinolytic agents in the management of thrombotic complications associated with vascular access devices. Nurs Clin North Am. 1993;28(4):899-909.
10. Kellerman S, Chan J, Jarvis W. Use of urokinase in pediatric hematology/oncology patients. Am J Infect Control. 1998;26(5): 502-506.
11. Krzywda EA. Predisposing factors, prevention and management of central venous catheter occlusions. J Intraven Nurs. June 1999;22(supp):S11-S17.
12. Hadaway LC. Major thrombotic and nonthrombotic complications. Loss of patency. J Intraven Nurs. 1998;21(supp):S143-S160.
13. Andris DA, Krzywda EA. Central venous catheters occlusion: successful management strategies. Medsurg Nurs. 1999;8(4):299-336.
14. Stokes DC, Rao BN, Mirro J, et al. Early detection and simplified management of obstructed Hickman and Broviac catheters. J Pediatr Surg. 1989;24:257.
15. Hurtubise MR, Bottino JC, Lawson M, et al. Restoring patency of occluded central venous catheters. Arch Surg. 1980;115:212-213.
16. Lawson M, Bottino JC, Hurtubise MR, et al. The use of urokinase to restore the patency of occluded central venous catheters. Am J Intraven Ther & Clin Nutr. 1982;Oct:29-32.
17. Wachs T. Urokinase administration in pediatric patients with occluded central venous catheters. J Intraven Nurs. 1990;13:100-102.
18. Ouwendyk M, Helferty M. Central venous catheter management: how to prevent complications. ANNA Journal. 1996;23(6):572-576.
19. Harris JL, Maguire D. Developing a protocol to prevent and treat pediatric central venous catheter occlusions. J Intraven Nurs. 1999;22:194-198.
20. Gabriel J. Fibrin sheaths in vascular access devices. Nursing Times. 1997;93(10):56-57.
21. Twardowski ZJ. High-dose intradialytic urokinase to restore the patency of permanent central vein hemodialysis catheters. Am J Kidney Dis. 1998;31(5):841-847.
22. Horne MK, Mayo DJ. Low-dose urokinase infusions to treat fibrinous obstruction of venous access devices in cancer patients. J Clin Oncol. 1997;15(7):2709-2714.
23. Carratalà J, Niubó J, Fernandez-Sevilla A, et al. Randomized, double-blind trial of an antibiotic-lock technique for prevention of gram-positive central venous catheter-related infection in neutropenic patients with cancer. Antimicrobial Agents and Chemotherapy. 1999;43(9):2200-2204.
24. Moureau N, Poole S, Murdock MA, et al. Central venous catheters in home infusion care: outcomes analysis in 50,470 patients. J Vasc Interv Radiol. 2002;13(10):1009-1016.
25. Timoney JP, Malkin MG, Leone DM, et al. Safe and cost effective use of alteplase for the clearance of occluded central venous access devices. J Clin Oncol. 2002;20(7):1918-1922.
26. Duszak R, Sacks D. Dialysis graft declotting with very low dose urokinase: is it feasible to use "less and wait?" J Vasc Interv Radiol. 1999;10(2):123-128.
27. Suyama T, Nishida M. Difference in thrombolytic effect between higher and lower molecular weight forms of urokinase. Thromb Haemostas. 1977;3:39-48.
28. Villaverde CA, Villaverde CJ. Arteriosclerosis thrombosis arterial. Rev Iberoamer Thromb Hemostasia. 1994;7:159-164.
29. Majors DS. Thrombolytic therapy with urokinase. ANNA Journal. 1996;23(6):627-628.
30. Clase CM, Crowther MA, Ingram AJ, et al. Thrombolysis for restoration of patency to haemodialysis central venous catheters: a systematic review. J Thrombos & Thrombolysis. 2001;11:127-136.
31. FDA Public Health Service. Important drug warning: safety information regarding the use of Abbokinase (urokinase). Available at: http://www.fda.gov/cber/ltr/abb0125599.html. Accessed December 18, 2000.
32. FDA Safety Information and Adverse Event Reporting Program. 2002 Safety Alert - Abbokinase (urokinase). Available at: http://www.fda.govmedwatch/SAFETY/2002/abbokinase.html. Accessed January 30, 2003.
33. Vedim Pharma: Urokinase Vedim. Drug information dept. Barcelona: UCB Pharma-Vedim Pharma; 1998.
34. Laboratorios Roger: Urokinase Roger. Terapéutica fibrinolitica. Drug information dept. Barcelona: Laboratorios Roger SA; 1990:25-33.
35. Northsea C. Continuous quality improvement: improving hemodialysis catheter patency using urokinase. ANNA Journal. 1996;23(6):567-571.
36. Rhoney DH, Coplin WM, Zaran FK, et al. Urokinase activity after freezing: implications for thrombolysis in intraventricular hemorrhage. Am J Health Syst Pharm. 1999;56:2047-2051.
37. Gale GB, O'Connor DM, Chu JY, et al. Restoring patency of thrombosed catheters with cryopreserved urokinase. J Parent Ent Nutr. 1984;8(3):298-299.
38. Isaac BF. Efficacy of cryopreserved recombinant alteplase for declotting thrombosed central catheters. Ann Pharmacother. 2000;34:533-534.
39. Davis SN, Vermeulen L, Shwartz BS, et al. Activity and dosage of alteplase dilution for clearing occlusions of venous-access devices. Am J Health Syst Pharm. 2000;57:1039-1045.
40. Castner D. The efficacy of reteplase in the treatment of thrombosed hemodialysis venous catheters. Nefrol Nurs J. 2001;28(4): 403-410.
41. Lee EK. Alteplase use for prevention of central line occlusion in a preterm infant. Ann Pharmacother. 2002;36(2):272-274.
42. Ponec D, Irwin D, Haire WD, et al. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial-the cardiovascular thrombolytic to open occluded lines (cool) efficacy trial. J Vasc Interv Radiol. 2001;12:951-955.
43. Jacobs BR, Haygood M, Hingl J. Recombinant tissue plasminogen activator in the treatment of central venous catheter occlusion in children. J Pediatr. 2001;139:593-596.
44. Atkinson JB, Bagnall HA, Bomperts E. Investigational use of tissue plasminogen activator (t-pa) for occluded central venous catheters. J Parenter Enteral Nutr. 1990;14:310-311.
45. Haire WD, Atkinson JB, Stephens LC, et al. Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: a double-blind randomized trial. Thromb Haemost. 1994;72:547-549.
46. Kleta R, Schleef J, Jurgens H. Tissue plasminogen activator and obstructed central venous catheters [letter]. Med Pediatr Oncol. 1998;30:376.
47. Streif S, Viertler E, Gabner I, et al. Successful central venous catheter thrombolysis with a single bolus recombinant tissue plasminogen activator (rt-pa). Thromb Haemost. January 1997; 78(S1):121.
48. Kandarpa K. Technical determinants of success in catheter-directed thrombolysis for peripheral arterial occlusions. J Vasc Intervent Radiol. 1995;6(supp):55S-61S.
49. Eyrich H, Walton T, Macon EJ, et al. Alteplase versus urokinase in restoring blood flow in hemodialysis-catheter thrombosis. Am J Health Syst Phar. 2002;59:1437-1440.